Does Pelargonium sidoides really help colds and bronchitis?

The root of Pelargonium sidoides contains a rich mixture of polyphenols, coumarins, and phenolic acids — particularly umckalin and related compounds — that work through several complementary mechanisms.

Blocking Viruses from Entering Cells

EPs 7630 interferes with the ability of respiratory viruses to attach to and enter airway cells. Laboratory studies found it inhibits replication of influenza A (H1N1, H3N2), respiratory syncytial virus (RSV), human coronavirus, parainfluenza virus, and coxsackievirus at concentrations achievable with standard dosing³. The extract targets viral surface proteins — the equivalent of jamming the lock before a virus can break in.

Stimulating Mucosal Immunity

Secretory IgA is the antibody that lines your respiratory mucosa and represents a first line of immune defense. In a placebo-controlled study of athletes after an exhausting running session, the extract raised secretory IgA in saliva and lowered blood levels of the inflammatory cytokines IL-6 and IL-15, as well as IL-15 in the nasal mucosa⁷. The authors suggest the extract modulates the immune response of the upper airways during intense exercise. The study was done in athletes after strenuous exercise, so it does not show the same effect in people with respiratory infections.

Enhancing Mucus Clearance

Cilia in the airways beat rhythmically to sweep mucus and trapped pathogens out of the lungs. EPs 7630 increases ciliary beat frequency, which helps clear debris and pathogens faster — one reason it seems to shorten the productive cough phase of bronchitis.

Preventing Bacterial Adhesion

P. sidoides extract also inhibits group A streptococci and other bacteria from binding to epithelial cells lining the throat, which may explain its traditional use for tonsillopharyngitis.

Dosing and Forms

EPs 7630 is available as a liquid tincture (30 drops three times daily) or tablets (30 mg three times daily for adults, lower for children). Treatment is typically 7–10 days. The standardized extract EPs 7630 is what the clinical trials used; look for products listing that designation or the equivalent milligram dose.

• Adults: 30 drops or 30 mg tablet, three times daily with water before meals
• Children: lower weight-based dosing; pediatric formulations are available
• Best started within 48 hours of symptom onset

It is generally well tolerated. Mild gastrointestinal complaints are occasionally reported. Rare hypersensitivity reactions have occurred; those with known allergies to the Geraniaceae family should use with caution.

See also our echinacea page and elderberry page for other evidence-based approaches to acute respiratory infections.

Cochrane Systematic Review (2013)

The Cochrane Collaboration's review by Timmer et al.² examined multiple randomized controlled trials of EPs 7630 across different respiratory infections. The review concluded that EPs 7630 was more effective than placebo in reducing symptom severity and duration for acute bronchitis and sinusitis in adults and children. The evidence was judged to be of moderate quality due to risk of bias in some trials, but the direction and magnitude of effect were consistent across studies.

Acute Bronchitis RCT — 468 Adults (2003)

Matthys et al.¹ conducted one of the foundational trials: 468 adults with acute bronchitis were randomized to EPs 7630 (30 drops three times daily) or placebo for 7 days. The Bronchitis Severity Score dropped by 5.9 ± 2.9 points in the EPs 7630 group compared with 3.2 ± 4.1 points in placebo — a statistically and clinically significant difference (p < 0.0001). Time to recovery and return to work was shortened by approximately 2 days.

Common Cold Phase 3 RCT (2019)

Riley, Lizogub, and colleagues⁴ conducted a phase 3 multicenter, double-blind, placebo-controlled trial in 105 adults with confirmed common cold. Participants received 40 mg EPs 7630 tablets or placebo three times daily for up to 10 days. By day 5, 55% of the EPs 7630 group rated their outcome as at least "major improvement" versus 15% of the placebo group. Clinical cure by day 10 was achieved by 45% in the treated group versus 12% in placebo. The mean symptom intensity difference score (SSID) favored EPs 7630 significantly (12.5 ± 4.4 vs 8.8 ± 6.8 points on day 5). Safety was excellent — adverse events occurred in fewer participants in the treated group (9.4%) than placebo (13.5%).

Pediatric Safety and Efficacy Review (2018)

Patiroglu and Tuncez Akyurek⁵ reviewed 8 RCTs conducted in children and adolescents using EPs 7630, covering acute bronchitis, tonsillopharyngitis, and upper respiratory infections. Across all trials, EPs 7630 demonstrated consistent symptom reduction and a favorable safety profile in pediatric populations. The evidence supported use in children presenting within 48 hours of symptom onset.

Meta-Analysis on Cough and Quality of Life (2022)

Kardos et al.⁶ pooled data from 11 randomized placebo-controlled trials involving 2,195 participants — 3 in children with acute bronchitis, 3 in adults with acute bronchitis, and 5 in adults with the common cold. EPs 7630 significantly reduced cough severity and led to earlier remission compared with placebo. Quality-of-life measures also favored the extract, with improvements in sleep, daily activity, and subjective wellbeing. The results were consistent across adult and pediatric populations and across infection types.

Antiviral Mechanisms (2011)

Schotz and Noldner³ demonstrated in laboratory studies that EPs 7630 at concentrations up to 100 µg/mL interfered with replication of a panel of respiratory viruses including seasonal influenza A (H1N1, H3N2), RSV, human coronavirus, parainfluenza, and coxsackievirus. The mechanism involves inhibition of viral surface glycoproteins (hemagglutinin and neuraminidase), preventing viral docking onto host cells. This broad-spectrum antiviral action — working at the entry step — is distinct from how most over-the-counter cold remedies work.

Overall Strength of Evidence

The evidence base for Pelargonium sidoides EPs 7630 is unusually robust for an herbal preparation: multiple phase 3 RCTs, a Cochrane review, pediatric safety data, and mechanistic studies all converge on the same conclusion. It is more effective than placebo at reducing symptom duration and severity for acute bronchitis and the common cold when started early. The effect size is moderate — roughly comparable to prescription antivirals for influenza — but with an excellent safety profile. Limitations include that most trials were industry-funded, and the extract used (EPs 7630) may not be interchangeable with all commercial products that simply list "Pelargonium sidoides" on the label.